专利号:US-7576211-B2 优先权日:2004-09-30 标题 :Synthesis of thienopyridinone compounds and related intermediates 发明人:DHANOA DALE S; BECKER OREN; NOIMAN SILVIA; CHEN DONGLI; MARANTZ YAEL; SHACHAM SHARON; HEIFETZ ALEXANDER; INBAL BOAZ; BAR-HAIM SHAY; MOHANTY PRADYUMNA; LOBERA MERCEDES; WU LAURENCE 权利人:EPIX DELAWARE INC 摘要:The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
专利号:US-11918657-B2 优先权日:2017-11-10 标 题 :Dendrimer delivery system and methods of use thereof 发明人:RANGARAMANUJAM KANNAN; SHARMA RISHI; SHARMA ANJALI; KANNAN SUJATHA; ZHANG ZHI; KAMBHAMPATI SIVA PRAMODH 权利人:UNIV JOHNS HOPKINS 摘要:Low-generation dendrimers containing a high density of surface hydroxyl groups, and methods of synthesis thereof are provided. In particular, oligo ethylene glycol (OEG)-like dendrimers with a high surface functional groups at relatively low generations (e.g. Ëœ120 hydroxyls in the third generation, with a size of just 1-2 nm) is described. Dendrimer formulations including one or more prophylactic, therapeutic, and/or diagnostic agents, and methods of use thereof are also described. The formulations are suitable for topical, enteral, and/or parenteral delivery for treating one or more diseases, conditions, and injuries in the eye, the brain and nervous system (CNS), particularly those associated with pathological activation of microglia and astrocytes.
专利号:US-2013130985-A1 优先权日:2010-04-01 标 题:Oxytocin peptide analogues 发明人:ALEWOOD PAUL; MUTTENTHALER MARKUS; DEKAN ZOLTAN 权利人:ALEWOOD PAUL; MUTTENTHALER MARKUS; DEKAN ZOLTAN 摘要:Peptide analogues of oxytocin are described together with methods of treating conditions ameliorated by modulating oxytocin receptor. The peptide analogues are seleno or telluro peptide analogues. Methods of synthesis of selenocysteine, tellurocysteine and oxytocin analogues are also described.
专利号:US-2006084805-A1 优先权日:2004-09-30 标题:Synthesis of thienopyridinone compounds and related intermediates
专利号:US-7982040-B2 优先权日:2004-05-17 标题 :Thienopyridinone compounds and methods of treatment 发明人:DHANOA DALE S; BECKER OREN; NOIMAN SILVIA; MOHANTY PRADYUMNA; CHEN DONGLI; LOBERA MERCEDES; WU LAURENCE; MARANTZ YAEL; INBAL BOAZ; HEIFETZ ALEXANDER; BAR-HAIM SHAY; SHACHAM SHARON 权利人:NANOTHERAPEUTICS INC 摘要:The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
专利号:US-9370515-B2 优先权日:2013-03-07 标题 :Mixed lineage kinase inhibitors and method of treatments 发明人:GOODFELLOW VAL S; NGUYEN THONG X; RAVULA SATHEESH B; GELBARD HARRIS A 权利人:CALIFIA BIO INC; UNIV ROCHESTER 摘要:Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.
1: Burckhardt A, Rakowsky A, Kahl E, Morchhale S, Mayer D, Panagiotou N, Permien L, Faesel N, Fendt M. Differential effects of orexin system activation on dizocilpine-induced schizophrenia-like behaviors in mice. Neuropeptides. 2026 Apr;116:102587. doi: 10.1016/j.npep.2026.102587. Epub 2026 Jan 28. 26(11):5329. doi: 10.3390/ijms26115329. 3: Konecny J, Misiachna A, Chvojkova M, Kleteckova L, Kolcheva M, Novak M, Prchal L, Ladislav M, Hemelikova K, Netolicky J, Hrabinova M, Kobrlova T, Karasova JZ, Pejchal J, Fibigar J, Vecera Z, Kucera T, Jendelova P, Zahumenska P, Langore E, Doderovic J, Pang YP, Vales K, Korabecny J, Soukup O, Horak M. Dizocilpine derivatives as neuroprotective NMDA receptor antagonists without psychomimetic side effects. Eur J Med Chem. 2024 Dec 15;280:116981. doi: 10.1016/j.ejmech.2024.116981. Epub 2024 Oct 18. 178:117201. doi: 10.1016/j.biopha.2024.117201. Epub 2024 Jul 24.
合成参考文献
摘要:Givvimani S, Qipshidze N, Tyagi N, Mishra PK, Sen U, Tyagi SC. Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease. Int J Physiol Pathophysiol Pharmacol. 2011;3(2):107–19. 参考文献:10.1155/2011/297153 摘要:Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast. 2011;2011():297153. 参考文献:10.1371/journal.pone.0022239 摘要:Holahan MR, Madularu D, McConnell EM, Walsh R, DeRosa MC. Intra-Accumbens Injection of a Dopamine Aptamer Abates MK-801-Induced Cognitive Dysfunction in a Model of Schizophrenia. PLoS ONE. 2011 Jul 13;6(7):e22239. doi: 10.1371/journal.pone.0022239.